Aurora Cannabis Files Full Year & Q4 Results

Ticker: ACB · Form: 6-K · Filed: 2025-06-18T00:00:00.000Z

Sentiment: neutral

Topics: results, financials, reporting

Related Tickers: ACB

TL;DR

ACB dropped full year and Q4 results on 6/18. Check the news release for details.

AI Summary

Aurora Cannabis Inc. (NASDAQ: ACB) filed a Form 6-K on June 18, 2025, reporting its full-year results and announcing its fiscal 2025 fourth-quarter performance. The filing includes a news release dated June 18, 2025, as Exhibit 99.1. Miguel Martin, CEO, signed the report.

Why It Matters

This filing provides investors with the latest financial performance data for Aurora Cannabis, crucial for understanding the company's operational health and future prospects in the cannabis market.

Risk Assessment

Risk Level: medium — Aurora Cannabis operates in the highly regulated and competitive cannabis industry, which carries inherent financial and market risks.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose is to report Aurora Cannabis Inc.'s full-year results and announce its fiscal 2025 fourth-quarter performance, as indicated by the news release dated June 18, 2025.

Who signed the Form 6-K on behalf of Aurora Cannabis Inc.?

Miguel Martin, the Chief Executive Officer, signed the report on behalf of Aurora Cannabis Inc.

What is the filing date of this report?

The filing date of this report is June 18, 2025.

Which exhibit is included with this Form 6-K?

Exhibit 99.1, a news release dated June 18, 2025, is submitted with this Form 6-K.

Does Aurora Cannabis file annual reports under Form 20-F or Form 40-F?

Aurora Cannabis files annual reports under Form 40-F, as indicated by the checkmark in the filing values section.

From the Filing

0001279569-25-000634.txt : 20250618 0001279569-25-000634.hdr.sgml : 20250618 20250618073739 ACCESSION NUMBER: 0001279569-25-000634 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250618 FILED AS OF DATE: 20250618 DATE AS OF CHANGE: 20250618 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURORA CANNABIS INC CENTRAL INDEX KEY: 0001683541 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38691 FILM NUMBER: 251055138 BUSINESS ADDRESS: STREET 1: 2207 90B STREET SW CITY: EDMONTON STATE: A0 ZIP: T6X 1V8 BUSINESS PHONE: 604-362-5207 MAIL ADDRESS: STREET 1: 409 GRANVILLE STREET STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 1T2 6-K 1 aurora_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File No. 001-38691 AURORA CANNABIS INC. (Translation of registrant's name into English) 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☐ Form 40-F ☒ SUBMITTED HEREWITH Exhibits Description 99.1 News release dated June 18, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AURORA CANNABIS INC. /s/ Miguel Martin Miguel Martin Chief Executive Officer Date: June 18, 2025 EX-99.1 2 ex991.htm NEWS RELEASE DATED JUNE 18, 2025 Exhibit 99.1 Aurora Cannabis Files Full Year Results and Announces Fiscal 2025 Fourth Quarter NASDAQ | TSX: ACB Achieves Record Annual Global Medical Cannabis Net Revenue 1 of $244.4 million, representing 39% YoY growth Delivers Record Adjusted EBITDA 1 of $49.7 million, representing 261% YoY growth Generates Annual Positive Free Cash Flow 1 of $9.9 million Sustains Strong Balance Sheet with ~$185.3 million of Cash and Debt-Free Cannabis Business 2 EDMONTON, AB, June 18, 2025 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora" ) (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2025 periods ending March 31, 2025. "We are pleased to report an exceptional year to our shareholders, highlighted by record annual global medical net revenue 1 , adjusted EBITDA 1 , and positive free cash flow 1 . These achievements underscore the thoughtful execution of our strategic plan, set us further apart from competitors, and strengthen our foundation for sustained and profitable growth," said Executive Chairman and Chief Executive Officer for Aurora, Miguel Martin. "Specific to Q4 2025, we ended our banner fiscal year by further strengthening our business model. International revenue more than doubled, representing 61% of global medical cannabis net revenue 1 . Plant propagation also increased significantly as we benefited from peak seasonality along with organic expansion. These top-line gains were complemented by a sharp year over year increase in adjusted EBITDA 1 profitability and the third quarter of positive free cash flow 1 generation." concluded Mr. Martin. _________________________________ 1 This press release includes certain non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP financial measures. See "Non-GAAP Measures" below for reconciliations of non-GAAP financial measures to GAAP financial measures. 2 Aurora's only remaining debt is non-recourse debt of $61.7

View on Read The Filing